MPM Bioimpact LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), MPM Bioimpact LLC reported 43 stock positions worth $666.6 million. Its top holding was Cullinan Therapeutics (CGEM) at 19.2% of the portfolio, followed by Insmed (INSM, 6.7%) and Olema Pharmaceuticals (OLMA, 4.8%). Compared with Q2 2024, it opened 10 new positions, sold out of 11, added to 20 and reduced 7. The biggest buy was Avidity Biosciences (RNAM, shares +451%) and the biggest sale an exit from Alkermes (ALKS).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001687078
- Portfolio Value
- $666.6M (Q3 2024)
- SEC Filing
- 0000950123-24-011026 ↗ filed Nov 13, 2024
Holdings Value
Holdings 43 stocks · $666.6M
| CGEM Cullinan Therapeutics Inc. | 19.21% | 7,648,268 | $128.0M | No change |
| INSM Insmed Inc. | 6.74% | 615,391 | $44.9M | No change |
| OLMA Olema Pharmaceuticals Inc. | 4.80% | 2,680,596 | $32.0M | Add +1.0% |
| RNAM Avidity Biosciences Inc. | 4.75% | 688,975 | $31.6M | Add +451.2% |
| CRNX Crinetics Pharmaceuticals Inc. | 4.03% | 525,845 | $26.9M | Reduce -5.6% |
| EWTX Edgewise Therapeutics Inc. | 3.67% | 917,166 | $24.5M | Add +23.8% |
| IOVA Iovance Biotherapeutics Inc. | 3.39% | 2,406,714 | $22.6M | Add +1.7% |
| NTRA Natera Inc. | 3.37% | 177,099 | $22.5M | Add +1.3% |
| RCKT Rocket Pharmaceuticals Inc. | 2.95% | 1,066,373 | $19.7M | New |
| MIRM Mirum Pharmaceuticals Inc. | 2.88% | 492,723 | $19.2M | Add +0.0% |
| RARE Ultragenyx Pharmaceutical Inc. | 2.75% | 329,733 | $18.3M | Reduce -13.3% |
| ITOS Iteos Therapeutics Inc. | 2.67% | 1,745,943 | $17.8M | No change |
| MLTX Moonlake Immunotherapeutics | 2.64% | 349,063 | $17.6M | Add +1.7% |
| LNTH Lantheus Holdings Inc. | 2.47% | 150,182 | $16.5M | Add +0.1% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.30% | 72,395 | $15.4M | Add +1.7% |
| IRON Disc Medicine Inc. | 2.30% | 311,761 | $15.3M | Add +2.0% |
| RLAY Relay Therapeutics Inc. | 2.16% | 2,033,041 | $14.4M | Add +59.5% |
| TWST Twist Bioscience Corp. | 2.00% | 294,930 | $13.3M | New |
| RVMD Revolution Medicines Inc. | 1.98% | 291,391 | $13.2M | Add +0.7% |
| GH Guardant Health Inc. | 1.72% | 499,170 | $11.5M | Reduce -0.2% |
| AKRO Akero Therapeutics Inc. | 1.69% | 392,544 | $11.3M | Add +1.7% |
| KALV Kalvista Pharmaceuticals Inc. | 1.56% | 896,915 | $10.4M | Add +1.7% |
| CMPX Compass Therapeutics Inc. | 1.56% | 5,641,894 | $10.4M | Add +12.7% |
| RNAC Cartesian Therapeutics Inc. | 1.52% | 629,423 | $10.1M | Add +142.4% |
| STRO Sutro Biopharma Inc. Com SHS | 1.47% | 2,832,064 | $9.8M | Reduce -6.9% |
| AQST Aquestive Therapeutics Inc. | 1.34% | 1,796,750 | $8.9M | New |
| JANX Janux Therapeutics Inc. | 1.17% | 171,105 | $7.8M | New |
| VKTX Viking Therapeutics Inc. | 1.15% | 120,982 | $7.7M | Add +1.7% |
| XENE Xenon Pharmaceuticals Inc. | 0.98% | 165,800 | $6.5M | New |
| STOK Stoke Therapeutics Inc. | 0.88% | 479,452 | $5.9M | New |
| RPTX Repare Therapeutics Inc. | 0.85% | 1,639,849 | $5.6M | No change |
| NTLA Intellia Therapeutics Inc. | 0.82% | 267,557 | $5.5M | Reduce -39.7% |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.81% | 1,465,801 | $5.4M | Add +1.1% |
| TRVI Trevi Therapeutics Inc. | 0.77% | 1,538,517 | $5.1M | Add +1.9% |
| WVE Wave Life Sciences Ltd. | 0.77% | 624,471 | $5.1M | New |
| ARCT Arcturus Therapeutics Holdin | 0.76% | 219,508 | $5.1M | New |
| HOWL Werewolf Therapeutics Inc. | 0.76% | 2,388,011 | $5.1M | No change |
| ADAPY Adaptimmune Therapeutics-ADR | 0.73% | 5,095,912 | $4.8M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.66% | 2,409,862 | $4.4M | Add +10.5% |
| PTCT PTC Therapeutics Inc. | 0.50% | 89,715 | $3.3M | New |
| ETNB 89BIO Inc. | 0.37% | 330,000 | $2.4M | Reduce -70.6% |
| RGNX Regenxbio Inc. | 0.08% | 50,000 | $525K | Reduce -91.0% |
| SLDB Solid Biosciences Inc. | 0.01% | 11,518 | $80K | New |
Portfolio Sells Q2 2024 → Q3 2024
| ALKS Alkermes PLC | Sold out | 0.00% | −2.09 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −1.96 |
| AVDL Avadel Pharmaceuticals plc | Sold out | 0.00% | −1.71 |
| XERS Xeris Biopharma Holdings Inc. | Sold out | 0.00% | −1.69 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −1.66 |
| HLVX Hillevax Inc. | Sold out | 0.00% | −1.45 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −1.39 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.33 |
| ETNB 89BIO Inc. | Reduce -70.6% | 0.37% | −1.03 |
| RGNX Regenxbio Inc. | Reduce -91.0% | 0.08% | −0.93 |
| IMTX Immatics NV | Sold out | 0.00% | −0.75 |
| NTLA Intellia Therapeutics Inc. | Reduce -39.7% | 0.82% | −0.72 |
| GH Guardant Health Inc. | Reduce -0.2% | 1.72% | −0.53 |
| VERV Verve Therapeutics Inc. | Sold out | 0.00% | −0.48 |
| ALLK Allakos LLC | Sold out | 0.00% | −0.05 |
| STRO Sutro Biopharma Inc. Com SHS | Reduce -6.9% | 1.47% | +0.08 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -5.6% | 4.03% | +0.15 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -13.3% | 2.75% | +0.32 |
Portfolio Buys Q2 2024 → Q3 2024
| RNAM Avidity Biosciences Inc. | Add +451.2% | 4.75% | +3.95 |
| RCKT Rocket Pharmaceuticals Inc. | New | 2.95% | +2.95 |
| TWST Twist Bioscience Corp. | New | 2.00% | +2.00 |
| EWTX Edgewise Therapeutics Inc. | Add +23.8% | 3.67% | +1.60 |
| AQST Aquestive Therapeutics Inc. | New | 1.34% | +1.34 |
| JANX Janux Therapeutics Inc. | New | 1.17% | +1.17 |
| XENE Xenon Pharmaceuticals Inc. | New | 0.98% | +0.98 |
| STOK Stoke Therapeutics Inc. | New | 0.88% | +0.88 |
| RLAY Relay Therapeutics Inc. | Add +59.5% | 2.16% | +0.87 |
| CMPX Compass Therapeutics Inc. | Add +12.7% | 1.56% | +0.78 |
| WVE Wave Life Sciences Ltd. | New | 0.77% | +0.77 |
| ARCT Arcturus Therapeutics Holdin | New | 0.76% | +0.76 |
| LNTH Lantheus Holdings Inc. | Add +0.1% | 2.47% | +0.60 |
| PTCT PTC Therapeutics Inc. | New | 0.50% | +0.50 |
| IOVA Iovance Biotherapeutics Inc. | Add +1.7% | 3.39% | +0.44 |
| RNAC Cartesian Therapeutics Inc. | Add +142.4% | 1.52% | +0.43 |
| NTRA Natera Inc. | Add +1.3% | 3.37% | +0.43 |
| OLMA Olema Pharmaceuticals Inc. | Add +1.0% | 4.80% | +0.34 |
| MLTX Moonlake Immunotherapeutics | Add +1.7% | 2.64% | +0.30 |
| AKRO Akero Therapeutics Inc. | Add +1.7% | 1.69% | +0.28 |
| MIRM Mirum Pharmaceuticals Inc. | Add +0.0% | 2.88% | +0.27 |
| RVMD Revolution Medicines Inc. | Add +0.7% | 1.98% | +0.24 |
| VKTX Viking Therapeutics Inc. | Add +1.7% | 1.15% | +0.17 |
| IRON Disc Medicine Inc. | Add +2.0% | 2.30% | +0.16 |
| TRVI Trevi Therapeutics Inc. | Add +1.9% | 0.77% | +0.07 |
| SLDB Solid Biosciences Inc. | New | 0.01% | +0.01 |
| KALV Kalvista Pharmaceuticals Inc. | Add +1.7% | 1.56% | −0.06 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +1.1% | 0.81% | −0.11 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +1.7% | 2.30% | −0.79 |
| ALXO Alx Oncology Holdings Inc. | Add +10.5% | 0.66% | −1.39 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $1.6B | CGEM, AKTS, LQDA, RVMD, CORT |
| Q1 2026 | 41 | $1.3B | DBVT, CGEM, AKTS, LQDA, ALMS |
| Q4 2025 | 38 | $874.0M | CGEM, MDGL, LQDA, TRVI, EWTX |
| Q3 2025 | 40 | $610.9M | MDGL, CGEM, RNAM, TRVI, EWTX |
| Q2 2025 | 44 | $577.2M | CGEM, MDGL, ZLAB, GH, SPRY |
| Q1 2025 | 43 | $581.7M | CGEM, MDGL, ZLAB, EWTX, LNTH |
| Q4 2024 | 47 | $704.4M | CGEM, CRNX, EWTX, INSM, NTRA |
| Q3 2024 | 43 | $666.6M | CGEM, INSM, OLMA, RNAM, CRNX |
| Q2 2024 | 44 | $643.5M | CGEM, INSM, OLMA, ITOS, CRNX |
| Q1 2024 | 38 | $622.0M | CGEM, GERN, IOVA, ZNTL, ITOS |